Fortress Biotech Inc banner

Fortress Biotech Inc
NASDAQ:FBIO

Watchlist Manager
Fortress Biotech Inc Logo
Fortress Biotech Inc
NASDAQ:FBIO
Watchlist
Price: 3.225 USD -4.02%
Market Cap: $100.1m

Fortress Biotech Inc
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Fortress Biotech Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Fortress Biotech Inc
NASDAQ:FBIO
Inventory
$11.8m
CAGR 3-Years
-8%
CAGR 5-Years
61%
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Inventory
$5B
CAGR 3-Years
11%
CAGR 5-Years
8%
CAGR 10-Years
11%
Gilead Sciences Inc
NASDAQ:GILD
Inventory
$1.8B
CAGR 3-Years
6%
CAGR 5-Years
1%
CAGR 10-Years
-1%
Amgen Inc
NASDAQ:AMGN
Inventory
$6.2B
CAGR 3-Years
8%
CAGR 5-Years
10%
CAGR 10-Years
10%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Inventory
$1.7B
CAGR 3-Years
54%
CAGR 5-Years
43%
CAGR 10-Years
40%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Inventory
$2.5B
CAGR 3-Years
1%
CAGR 5-Years
5%
CAGR 10-Years
26%
No Stocks Found

Fortress Biotech Inc
Glance View

Market Cap
100.1m USD
Industry
Biotechnology

Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 173 full-time employees. The company went IPO on 2011-11-17. Fortress has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, and at its partner companies. Its product candidates span six market areas, including oncology, rare diseases and gene therapy. The firm's commercialized products include Ximino, Targadox, Exelderm, Ceracade, Luxamend and Accutane. Its late-stage product candidates include Intravenous (IV) Tramadol, CUTX-101, MB-107 and MB-207, Cosibelimab, CK-101, CAEL-101, Triplex and CEVA101. Its product candidates also consist of MB-102 (CD123 CAR T for BPDCN), MB-101 (IL13Ra2 CAR T for Glioblastoma), MB-104, MB-106, MB-103, AVTS-001, CK-103 and ConVax. The firm operates in two operating and reportable segments: Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.

FBIO Intrinsic Value
HIDDEN
Show

See Also

What is Fortress Biotech Inc's Inventory?
Inventory
11.8m USD

Based on the financial report for Sep 30, 2025, Fortress Biotech Inc's Inventory amounts to 11.8m USD.

What is Fortress Biotech Inc's Inventory growth rate?
Inventory CAGR 5Y
61%

Over the last year, the Inventory growth was 0%. The average annual Inventory growth rates for Fortress Biotech Inc have been -8% over the past three years , 61% over the past five years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett